Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
-The combination was generally well tolerated and all patients completed 12 weeks of treatment-
-Mean within-group absolute improvement from baseline in lung function of 4.4 (p=0.009) and 3.0 (p=0.026) percentage points at week 4 and through 12 weeks of treatment, respectively, in patients who received VX-661 (100 mg once daily) in combination with ivacaftor (150 mg every 12 hours)-
-Data were consistent with prior Phase 2 studies of VX-661 and ivacaftor and support ongoing Phase 3 program evaluating VX-661 in combination with ivacaftor in people with one or two copies of the F508del mutation-
Relevant link:
